Presentation is loading. Please wait.

Presentation is loading. Please wait.

Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide.

Similar presentations


Presentation on theme: "Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide."— Presentation transcript:

1 Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance  Meighan Palazzo, Gunjan L. Shah, Olivia Copelan, Kenneth Seier, Sean M. Devlin, Molly Maloy, Sheila Kenny, Hani Hassoun, Neha S. Korde, Nikoletta Lendvai, Alexander M. Lesokhin, Sham Mailankody, David J. Chung, Guenther Koehne, C. Ola Landgren, Heather Landau, Sergio A. Giralt, Miguel-Angel Perales  Biology of Blood and Marrow Transplantation  Volume 24, Issue 4, Pages (April 2018) DOI: /j.bbmt Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Response by vaccine subtype.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Percentage of patients on lenalidomide maintenance versus not on LM who responded (excluding patients who retained immunity or were not evaluable). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions


Download ppt "Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide."

Similar presentations


Ads by Google